2022 SIC意见书：肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用：沙库巴曲/缬沙坦的疗效、机械效应和实际应用

2022-04-22 意大利心脏病学会 Eur J Intern Med

2022年4月，意大利心脏病学会(SIC)发布了肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用意见书。肾素-血管紧张素-醛固酮系统（RAAS）抑制是射血分数降低心力衰竭（HFrEF）药物治疗的主

中文标题：

英文标题：

Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology

发布机构：

意大利心脏病学会

发布日期：

2022-04-22

简要介绍：

2022年4月，意大利心脏病学会(SIC)发布了肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用意见书。肾素-血管紧张素-醛固酮系统（RAAS）抑制是射血分数降低心力衰竭（HFrEF）药物治疗的主要手段。本文主要介绍了沙库巴曲/缬沙坦的疗效、机械效应和实际应用。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=e4a391c002a24e81, title=2022 SIC意见书：肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用：沙库巴曲/缬沙坦的疗效、机械效应和实际应用, enTitle=Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology, guiderFrom=Eur J Intern Med, authorId=0, author=, summary=2022年4月，意大利心脏病学会(SIC)发布了肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用意见书。肾素-血管紧张素-醛固酮系统（RAAS）抑制是射血分数降低心力衰竭（HFrEF）药物治疗的主, cover=https://img.medsci.cn/20220428/1651113431909_1608702.png, journalId=0, articlesId=null, associationId=1287, associationName=意大利心脏病学会, associationIntro=, copyright=0, guiderPublishedTime=Fri Apr 22 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年4月，意大利心脏病学会(SIC)发布了肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用意见书。肾素-血管紧张素-醛固酮系统（RAAS）抑制是射血分数降低心力衰竭（HFrEF）药物治疗的主要手段。本文主要介绍了沙库巴曲/缬沙坦的疗效、机械效应和实际应用。</span></p>, tagList=[TagDto(tagId=335, tagName=心力衰竭), TagDto(tagId=103688, tagName=肾素-血管紧张素-醛固酮系统抑制剂)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3020, appHits=211, showAppHits=0, pcHits=197, showPcHits=2808, likes=3, shares=46, comments=4, approvalStatus=1, publishedTime=Thu Apr 28 15:35:00 CST 2022, publishedTimeString=2022-04-22, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Thu Apr 28 10:40:28 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 04:56:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 SIC意见书：肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用：沙库巴曲_缬沙坦的疗效、机械效应和实际应用.pdf)])

2022 SIC意见书：肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用：沙库巴曲_缬沙坦的疗效、机械效应和实际应用.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1222592, encodeId=78cb12225927b, content=我翻好了，不知怎么上传, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu May 26 13:36:29 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215507, encodeId=a532121550ef0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Fri Apr 29 07:22:20 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215477, encodeId=830212154e7b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=664f1346112, createdName=caihanjiong, createdTime=Thu Apr 28 23:16:01 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
2022-05-26 forvalen

我翻好了，不知怎么上传

52 0
[GetPortalCommentsPageByObjectIdResponse(id=1222592, encodeId=78cb12225927b, content=我翻好了，不知怎么上传, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu May 26 13:36:29 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215507, encodeId=a532121550ef0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Fri Apr 29 07:22:20 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215477, encodeId=830212154e7b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=664f1346112, createdName=caihanjiong, createdTime=Thu Apr 28 23:16:01 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
2022-04-29 ms3000000376140643

学习学习

51 0
[GetPortalCommentsPageByObjectIdResponse(id=1222592, encodeId=78cb12225927b, content=我翻好了，不知怎么上传, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu May 26 13:36:29 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215507, encodeId=a532121550ef0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c40a6387446, createdName=ms3000000376140643, createdTime=Fri Apr 29 07:22:20 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215477, encodeId=830212154e7b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=664f1346112, createdName=caihanjiong, createdTime=Thu Apr 28 23:16:01 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
2022-04-28 caihanjiong

学习了

54 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2022 SIC意见书：肾素-血管紧张素-醛固酮系统抑制剂在心衰患者中的应用：沙库巴曲/缬沙坦的疗效、机械效应和实际应用

相关指南

科室

工具

服务